Strong Q3 Performance: Danaher (NYSE: DHR) reported robust revenue growth and adjusted earnings per share that surpassed analyst estimates, driven by strong profitability in its Biotechnology segment. Analyst Sentiment Divided: While UBS reiterated a "Buy" rating for Danaher, other analyses, such…
Danaher (NYSE: DHR) reported strong Q3 2026 earnings per share of $2.11, surpassing estimates, despite a slight revenue miss. The company highlighted improving customer demand and faster core revenue growth, excluding respiratory revenue, exceeding internal expectations. Key financial metrics…
Every article on every company, fresh through the day, plus search for any ticker. Pop in your email to unlock it.
You'll get Gro's newsletter too. Leave any time in one click.
Articles from Financial Modeling Prep.
